Kumar Raja, Ph.D
Kumar Raja is Brookline's Senior Biotechnology Analyst. Dr. Raja started his equity research career as a Senior Associate Analyst on the highly ranked Citi research biotechnology team. His expertise includes bottoms-up scientific and financial analysis on companies across therapeutics areas and a spectrum of market capitalizations. He has deep knowledge on drug development, intellectual property, FDA and EMA regulations, reimbursement coverage and clinical science. Dr. Raja conducted post-doctoral research at the Mayo Clinic to understand the epigenetic causes of cancer and at Los Angeles Biomedical Research Institute to elucidate the molecular mechanisms concerning the role of human bone marrow stem cells in normal and leukemic hematopoisesis.
Dr. Raja received his Ph.D. in Biological Sciences from Bowling Green State University and M.B.A. from University of California, San Diego.
Sally Yanchus, MBA
Sally Yanchus is a Senior Life Sciences Analyst at Brookline. Ms. Yanchus has significant experiences as a healthcare analyst on both the buy and the sell sides. She was most recently the global healthcare analyst at Tradewinds Global Investments, a division of Nuveen. Prior to that she was a pharmaceutical and biotech analyst at Bessemer Investments and a biotech analyst at The Galleon Group. Ms Yanchus covered life sciences stocks on the sell side at Oppenheimer & Co., Lehman Brothers, and Morgan Stanley.
She graduated magna cum laude and Phi Betta Kappa from Wellesley College with a B.A. in Economics, and received her MBA in Finance from Columbia University’s School of Business.
In 2018, Brookline Capital Markets entered into a strategic research partnership agreement with Edison Investment Research, an independent research and advisory firm with a global presence and deep multi-sector experience. Brookline distributes Edison research reports, broadening Brookline's equity research coverage portfolio. Edison is an investment research and advisory company with offices in North America, Europe, the Middle East and Asia-Pacific. Edison is renowned for its equity research platform, aimed at improving visibility and increasing investor understanding. Research on client companies includes delving into business models, strategies, forecasts and valuations. Edison follows 10 sectors and 700 stocks.
The Edison-Brookline team, led by Maxim Jacobs and Nathaniel Calloway, Ph.D., has enabled Brookline to leverage the scale of Edison's resources and create a dual-platform research model, expanding the firm's aggregate healthcare research offering to over 30 companies.
Maxim is a C.F.A. charter holder and graduated magna cum laude with a B.A. in Economics from the University of Pennsylvania. Dr. Calloway holds a Ph.D. in Chemistry from Cornell University.
Edison Research Partnership